PEG-Intron

(Peginterferon alfa-2b)

Phase 3Small molecule

Peginterferon alfa-2b is used to treat chronic hepatitis C and melanoma by boosting the immune system to fight these diseases.[1] PEG-Intron is currently being investigated across 40 indications[3], with its most advanced program in Phase 3.[1]

PEG-Intron is one of 896 small molecule programs targeting AIDS. It is currently in Phase 3.

Indications

Total Trials

Active Trials

895

Competitors

Pipeline

Status by Indication[3][1]

Indication

AIDSActive, not recruiting

Polycythemia VeraActive, not recruiting

Peritoneum CancerActive, not recruiting

HIV InfectionActive, not recruiting

Cirrhosis of LiverActive, not recruiting

MetastasisActive, not recruiting

ParagangliomaActive, not recruiting

Hepatitis B Virus InfectionActive, not recruiting

Kidney CancerActive, not recruiting

HepatitisActive, not recruiting

AIDSPhase 3

Active, not recruiting

Polycythemia VeraPhase 3

Active, not recruiting

Peritoneum CancerPhase 1

Active, not recruiting

HIV InfectionPhase 3

Active, not recruiting

Cirrhosis of LiverPhase 3

Active, not recruiting

MetastasisPhase 3

Active, not recruiting

ParagangliomaPhase 2

Active, not recruiting

Hepatitis B Virus InfectionPreclinical

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

HepatitisPhase 3

Active, not recruiting

Showing 10 of 40 indications

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Phase 3

77 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

Intron a

Systemic Therapy

1 10

Abecma

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Recruiting

Hepatitis B

NCT05988879

Q4 2028

Post-ApprovalNot yet recruiting

Chronic Hepatitis

NCT07231276

Q4 2029

Post-ApprovalRecruiting

Chronic Hepatitis

NCT05182463

Q2 2031

Phase 2Active, not recruiting

Malignant Melanoma

NCT00539591

Clinical

Trials by Indication[1]

Chronic Hepatitis43 trials

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Completed· Roche logo

Roche··NCT01280656·660 enrolled

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

Completed·MMedtronic Corporate Technologies and New Ventures·Phase 2·NCT00919633·116 enrolled

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT00781274·32 enrolled

Show 40 more trials

Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 3·NCT01590225

New Strategy Study of Functional Cure of Chronic Hepatitis B

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT02605252·120 enrolled

HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin

Terminated·AAnna Cruceta·Phase 3·NCT01718301·108 enrolled

Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)

Completed· Merck & Co. logo

Merck & Co.··NCT00724451·1,128 enrolled

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00797745·111 enrolled

Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)

Completed· Merck & Co. logo

Merck & Co.··NCT00724295·1,077 enrolled

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT00780416·189 enrolled

Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01023035·687 enrolled

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01390844·282 enrolled

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00686881·261 enrolled

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Completed·XXiamen Amoytop Biotech Co., Ltd.·Phase 3·NCT04846491·475 enrolled

Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)

Completed· Merck & Co. logo

Merck & Co.··NCT00863109·133 enrolled

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Completed· Roche logo

Roche·Phase 4·NCT00087607·385 enrolled

Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00686790·68 enrolled

Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00705666·789 enrolled

Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00705432·1,472 enrolled

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00302081·696 enrolled

Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00104052·107 enrolled

Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00049842·540 enrolled

Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 4·NCT07231276·113 enrolled

Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT00687544·11 enrolled

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00910624·168 enrolled

PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Completed· Roche logo

Roche··NCT01066819·1,656 enrolled

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00423670·765 enrolled

PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Completed· Roche logo

Roche··NCT01066793·2,343 enrolled

PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)

Completed·SSchering-Plough·Phase 4·NCT00724620·103 enrolled

Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00048724·631 enrolled

ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)

Terminated· Merck & Co. logo

Merck & Co.··NCT00856024·902 enrolled

Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT02973646·100 enrolled

Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C

Terminated·BBausch Health Americas, Inc.·Phase 2·NCT00305383·100 enrolled

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Completed·XXiamen Amoytop Biotech Co., Ltd.··NCT03181113·473 enrolled

The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01425203·238 enrolled

Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.

Completed·AANRS, Emerging Infectious Diseases·Phase 2/3·NCT00323804·372 enrolled

Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00723632·901 enrolled

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT00255034·146 enrolled

Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT05182463·5,000 enrolled

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2/3·NCT00689390·1,954 enrolled

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT00780910·109 enrolled

Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection

Completed·FFGK Clinical Research GmbH·Phase 4·NCT00351403·390 enrolled

Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection

Unknown status·TTheodor Bilharz Research Institute·Phase 3·NCT01653236·40 enrolled

Hepatitis C15 trials

Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C

Completed·RRomark Laboratories L.C.·Phase 2·NCT00418054·40 enrolled

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00015652·24 enrolled

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00018031·36 enrolled

Show 12 more trials

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT01440595·5 enrolled

Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)

Terminated· Merck & Co. logo

Merck & Co.··NCT00723879·115 enrolled

Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00704522·601 enrolled

Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)

Completed· Merck & Co. logo

Merck & Co.··NCT00727259·1,995 enrolled

Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)

Completed· Merck & Co. logo

Merck & Co.··NCT00723892·614 enrolled

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01366638·79 enrolled

Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)

Completed·SSchering-Plough··NCT00705263·113 enrolled

Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00759109·150 enrolled

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Terminated· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1/2·NCT01701063·42 enrolled

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT01468584·10 enrolled

Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT00255008·121 enrolled

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT01466192·108 enrolled

Fibrosis2 trials

Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03919565·120 enrolled

Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03920605·100 enrolled

Metastatic Melanoma1 trial

Peginterferon and TIL Therapy for Metastatic Melanoma

Completed·IInge Marie Svane·Phase 1/2·NCT02379195·12 enrolled

Induction Therapy1 trial

Pegintron Induction Therapy in HCV Non-Responders

Completed·FFoundation for Liver Research·Phase 3·NCT00363259·110 enrolled

15 more indications

HIV1 trial

Zidovudine Levels in HIV Infected Patients Being Treated for HCV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00059358·16 enrolled

Effectiveness1 trial

Safety and Effectiveness of PEG-Intron in HIV-Infected Patients

Completed·SSchering-Plough·Phase 2·NCT00005012·250 enrolled

Metastatic Solid Tumors1 trial

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00701298·30 enrolled

Pediatric1 trial

5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00761735·94 enrolled

Hepatitis B1 trial

Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients

Recruiting·GGuangzhou 8th People's Hospital··NCT05988879·60 enrolled

TED1 trial

Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00724373·442 enrolled

Melanoma1 trial

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Completed·HHassane M. Zarour, MD·Phase 1·NCT02112032·43 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01016912·51 enrolled

Adjuvant1 trial

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00415857·5 enrolled

Cirrhosis1 trial

Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00687219·102 enrolled

Children1 trial

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00006325·54 enrolled

Osteosarcoma1 trial

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Completed·CChildren's Oncology Group·Phase 3·NCT00134030·1,334 enrolled

Craniopharyngioma1 trial

Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Terminated·PPediatric Brain Tumor Consortium·Phase 2·NCT01964300·19 enrolled

Malignant Melanoma1 trial

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT00539591·29 enrolled

Unspecified1 trial

PegIntron Injection Surveillance Plan (Study P04123)

Completed· Merck & Co. logo

Merck & Co.··NCT00723931·1,267 enrolled

Sources

References

[1]
ClinicalTrials.gov — 77 trial records for Peginterferon alfa-2b. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peginterferon alfa-2b compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peginterferon alfa-2b. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interferon Alpha/beta Receptor Agonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

PEG-Intron

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Q4 2029

Q2 2031

Trials by Indication[1]

Chronic Hepatitis43 trials

Hepatitis C15 trials

Fibrosis2 trials

Metastatic Melanoma1 trial

Induction Therapy1 trial

HIV1 trial

Effectiveness1 trial

Metastatic Solid Tumors1 trial

Pediatric1 trial

Hepatitis B1 trial

TED1 trial

Melanoma1 trial

Safety and Efficacy1 trial

Adjuvant1 trial

Cirrhosis1 trial

Children1 trial

Osteosarcoma1 trial

Craniopharyngioma1 trial

Malignant Melanoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News